Edgewise Therapeutics, Inc.

Edgewise Therapeutics is a biotech company developing drugs to treat muscle and heart disorders. Its main experimental drug, sevasemten, is being tested in patients with Duchenne and Becker muscular dystrophy, rare inherited conditions that cause progressive muscle weakness. The company is also working on drugs for hypertrophic cardiomyopathy (a thickening of the heart muscle) and heart failure. These are early-stage drugs still in clinical trials, meaning they are being tested in patients to see if they work and are safe.